Dermapharm Holding SE successfully maintains growth trend as planned

Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today published its results for the first nine months of 2022.

READ MORE

Dermapharm - Pharmaceutical Excellence “Made in Germany”

Dermapharm is a rapidly growing manufacturer of branded pharmaceuticals. Founded in 1991, the Company is based in Grünwald near Munich. The Company's integrated business model comprises in-house development, production and the distribution of brand products by a trained pharmaceutical sales force. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Europe (primarily in Germany) and the United States.

Read Annual Report 2021

Dermapharm SE Arbeit im Labor

Current Company Presentation

Comprehensive overview of the Dermapharm Group.

Download now

Dermapharm SE Icon Glasflasche

PHARMACEUTICAL INGREDIENTS

>380

Dermapharm SE Icon Bündel Geldscheine

REVENUE 2021

EUR 942.9 million

Dermapharm SE Icon Stift und Papier

MARKETING AUTHORISATIONS

>1,200

Dermapharm SE Icon steigender Aktienkurs

EBITDA 2021  (unadjusted)

EUR 354.4 million

Reasons to invest

Clear focus on Germany as a production location
Rapidly growing pharmaceutical manufacturer in selected niche markets
Own R&D with about 40 ongoing development projects in the pipeline
Successful track record in acquisitions
Increasing expansion of international presence

TO FACTSHEET 9M 2022

Dermapharm SE Icon Glasflasche

PHARMACEUTICAL INGREDIENTS

>380

Dermapharm SE Icon Stift und Papier

MARKETING AUTHORISATIONS

>1,200

Dermapharm SE Icon Bündel Geldscheine

REVENUE 2021

EUR 942.9 million

Dermapharm SE Icon steigender Aktienkurs

EBITDA 2021  (unadjusted)

EUR 354.4 million

Share

Corporate News & Ad-Hoc-Releases

03/22/2023

Dermapharm Holding SE: dividend 2022

Grünwald, 22. März 2023 - At its meeting today, the Board of Management of Dermapharm Holding SE resolved to propose to the Company's Annual General Meeting, which is exxpected to be held on 14 June 2023, the distribution of a dividend for the 2022 financiel year amounting to EUR 1.05 per no-par value share carrying dividend rights (previous year: EUR 2.17 per share).

Read more

Dermapharm Holding SE's revenue exceeds one billion for the first time

Grünwald, 14 March 2023 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today published its unaudited preliminary consolidated figures (IFRS) for financial year 2022. Despite the difficult macroeconomic environment, Dermapharm succeeded in maintaining its growth trajectory.

Read more

Dermapharm Holding SE intensifies its internationalisation efforts by acquiring Arkopharma

The Arkopharma acquisition closed today, Thursday, 5 January 2023. Arkopharma was founded in 1980 in Carros, a suburb of Nice, France, with a focus on phytotherapy.

Read more

all news at a glance

Financial Reports & Presentations

Recent Publications

pdf

DERMAPHARM HOLDING SE - INTERIM STATEMENT THIRD QUARTER 2022
(437 KB)

pdf

pdf

DERMAPHARM HOLDING SE Q3/2022 PRESENTATION
(1 MB)

pdf

pdf

DERMAPHARM HOLDING SE - HALF-YEAR FINANCIAL REPORT 2022
(1 MB)

pdf

pdf

DERMAPHARM HOLDING SE - H1/2022 PRESENTATION
(1 MB)

pdf

pdf

DERMAPHARM HOLDING SE - HALF-YEAR FINANCIAL REPORT 2021
(2 MB)

pdf

pdf

DERMAPHARM HOLDING SE - INTERIM STATEMENT THIRD QUARTER 2021
(1 MB)

pdf

pdf

DERMAPHARM HOLDING SE - INVESTOR AND ANALYST CONFERENCE CALL Q3 2021
(511 KB)

pdf

pdf

DERMAPHARM HOLDING SE ‒ ANNUAL REPORT 2021
(4 MB)

pdf

pdf

DERMAPHARM HOLDING SE - FY 2021 PRESENTATION
(1 MB)

pdf

pdf

DERMAPHARM HOLDING SE - INTERIM STATEMENT FIRST QUARTER 2021
(1 MB)

pdf

Our brands and location

Find your way to our subsidiaries at different locations worldwide on a clearly arranged map!

see more

Dermapharm SE Weltausschnitt Europa

IR Newsletter Service

We will be happy to include you in our news service!
Please fill out the form and you will receive information on investor relations topics.

To registration

Sustainability within the Dermapharm Group

Are you interested in sustainability? So are we! Read the details in our CSR report or find information on our investment in energy-efficient buildings or the resource-conserving use of raw materials directly under the highlights.

read more

Dermapharm SE Photovoltaikanlage im Sonnenuntergang